The independent source for health policy research, polling, and news.
KFF’s policy research provides facts and analysis on a wide range of policy issues and public programs.
KFF designs, conducts and analyzes original public opinion and survey research on Americans’ attitudes, knowledge, and experiences with the health care system to help amplify the public’s voice in major national debates.
KFF Health News is a national newsroom that produces in-depth journalism about health issues and is one of the organization’s core operating programs.
During the Medicare open enrollment period for 2020, Medicare beneficiaries had an average of 24 Medicare Advantage prescription drug plans and 28 stand-alone Part D prescription drug plans to choose from for their coverage. Despite having so many Medicare options, relatively few Medicare private plan enrollees opted to switch their coverage.
This annual survey of employers provides a detailed look at trends in employer-sponsored health coverage, including premiums, worker contributions, cost-sharing provisions, offer rates, and more. This year’s report also looks at how employers are addressing a growing need for mental health services.
Annual family premiums for employer-sponsored health insurance average $22,463 this year, similar to last year ($22,221), the 2022 benchmark KFF Employer Health Benefits Survey finds. On average, workers this year are contributing $6,106 toward the cost of family premium, with employers paying the rest.
Few Voters Know About the Medicare Drug Provisions in the Inflation Reduction Act, Though Seniors are More Aware and Would Be Likely to Vote for Candidates Who Support Them About a month ahead of the 2022 midterm election, abortion continues to grow as a motivating issue for voters, especially among Democrats and those living in…
Leading up to the November 2022 midterm elections, abortion access is motivating majorities of Democratic women, women under 50 and and Democratic voters in states with abortion bans. For older voters, some health care issues related to Medicare costs are resonating.
The recent passage of the Inflation Reduction Act of 2022 (IRA) includes a number of climate, tax, and health care provisions and prescription drug reforms. This policy watch explores the potential impacts of the Inflation Reduction Act on overall Medicaid spending as well as implications for Medicaid beneficiaries.
In this column for the JAMA Forum, KFF's Larry Levitt explores the Medicare drug-price negotiation provisions and other significant drug-price changes in the Inflation Reduction Act and their potential to lead to further efforts to address health care costs.
The pressures of inflation are far reaching, affecting providers, insurers, government programs such as Medicaid and Medicare, and, ultimately, the American people. Over the coming months, health care providers and insurers will wrap up pricing negotiations and set premiums for the next year. Amid these negotiations, there remain big questions as to how economic policy and legislation such as the Inflation Reduction Act will influence pricing and payment for insurance and health care, including prescription drugs, and who will bear the brunt of rising costs.
This analysis provides the latest data about Medicare Part D enrollment, premiums, and cost sharing in 2022 and trends over time, including information about stand-alone prescription drug plans (PDPs) and Medicare Advantage prescription drug plans.
Larry Levitt writes about the political and practical impact of the health care provisions in the Inflation Reduction Act in The New York Times guest essay, “The Biggest Health Care Reform in a Decade Could Lower Your Costs.”
© 2025 KFF